Ensifentrine

• Description:

  Ensifentrine is a PDE3/4 inhibitor, although its affinity for PDE3 (IC50: 0.4 nM) is 3,440 times higher than that for PDE4 (IC50: 1479 nM), that is under clinical development for the treatment of asthma and COPD and, potentially, cystic fibrosis.

• Stability:

  ≥ 2 years

• Purity:

  >98% (HPLC)

• Weight:

  477.565

• Molecular Formula:

  C26H31N5O4

• Notes:

  Research use only, not for human use.

• Receptor:

  ——

• CAS Number:

  1884461-72-6